Formerly a research leader at CHOP, High pursued
groundbreaking preclinical investigations in hemophilia B
gene therapy and provided scientific expertise to previous
gene therapy trials in hemophilia and other genetic disorders at CHOP before moving to Spark Therapeutics, which was spun off from CHOP in 2013.